HC Bioscience utilizes engineered tRNA to modify protein translation within cells, allowing for the correction of disease-causing mutations without altering DNA or mRNA. This approach enables the production of complete, functional proteins from faulty genes, addressing genetic disorders at the translational level.
Funding
$72.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVTVFounders
Product
Problem
Many genetic disorders are caused by mutations that lead to premature termination codons (PTCs) in mRNA, resulting in truncated, non-functional proteins. Traditional gene therapies often involve altering DNA or mRNA, which can have unintended consequences and may not always restore proper protein function.
Solution
HC Bioscience leverages engineered transfer RNA (tRNA) to precisely modify protein translation within cells, enabling the correction of disease-causing mutations without altering the underlying DNA or mRNA. Their PTCx platform works by overwriting premature termination signals, allowing the cell's translational machinery to insert the desired amino acid and produce complete, functional proteins from faulty genes. This approach restores proper protein function while maintaining the cell's natural regulatory processes.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing treatments for genetic disorders caused by premature termination codons.
Features
- Engineered tRNA platform for precise protein editing at the translational level
- Overwrites premature termination codons (PTCs) to enable full-length protein production
- Maintains the cell's natural regulatory processes by avoiding alterations to DNA or mRNA
- Addresses genetic disorders caused by mutations leading to truncated proteins